多发性骨髓瘤微小残留病的检测方法及临床应用

doi:10.3760/cma.j.issn.1673-422X.2018.01.013

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (1): 56-.doi: 10.3760/cma.j.issn.1673-422X.2018.01.013

多发性骨髓瘤微小残留病的检测方法及临床应用

刘小兰，关涛，苏丽萍

030013 太原，山西省肿瘤医院（山西省第三人民医院）血液科

出版日期:2018-01-08 发布日期:2018-02-12
通讯作者: 苏丽萍 E-mail:sulp2005@sohu.com

Detection and clinical application of minimal residual disease in multiple myeloma

Liu Xiaolan, Guan Tao, Su Liping

Department of Hematology, Shanxi Provincial Cancer Hospital (Third People′s Hospital of Shanxi Province), Taiyuan 030013, China

Online:2018-01-08 Published:2018-02-12
Contact: Su Liping E-mail:sulp2005@sohu.com

摘要/Abstract

摘要： 微小残留病（MRD）作为多发性骨髓瘤（MM）的一个极为重要的预后因素，其检测方法主要包括以细胞为基础的检测方法（多参数流式细胞术）和分子学检测方法（包括PCR和基因测序），各检测方法具有明显的优缺点。在临床应用方面，对于接受造血干细胞移植和传统化疗的患者，MRD阴性均可明显延长无进展生存期和总生存期。而且，MRD状态对治疗方案的选择具有重要意义。

关键词: 多发性骨髓瘤；肿瘤, 残余

Abstract: Minimal residual disease (MRD) is a very important prognostic factor in multiple myeloma (MM). The major types of MRD tests include cellbased test (multiparameter flow cytometry) and molecular tests (including PCR and gene sequencing), and the various techniques have inherent advantages and limitations. In clinical application, MRD negative can significantly prolong progressionfree survival and overall survival of patients who receive hematopoietic stem cell transplantation and conventional chemotherapy. Moreover, the MRD status is of great significance to the selection of treatment options.

Key words: Multiple myeloma, Neoplasm, residual

刘小兰，关涛，苏丽萍. 多发性骨髓瘤微小残留病的检测方法及临床应用[J]. 国际肿瘤学杂志, 2018, 45(1): 56-.

Liu Xiaolan, Guan Tao, Su Liping. Detection and clinical application of minimal residual disease in multiple myeloma[J]. Journal of International Oncology, 2018, 45(1): 56-.

参考文献

［1］ Munshi NC, AvetLoiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a metaanalysis［J］. JAMA Oncol, 2017, 3(1): 2835. DOI: 10.1001/jamaoncol.2016.3160. ［2］Landgren O, Gormley N, Turley D, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDANCI roundtable symposium［J］. Am J Hematol, 2014, 89(12): 11591160. DOI: 10.1002/ajh.23831. ［3］ Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders［J］. Haematologica, 2008, 93(3): 431438. DOI: 10.3324/haematol.11080. ［4］ Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma Ⅸ Study［J］. J Clin Oncol, 2013, 31(20): 25402547. DOI: 10.1200/JCO.2012.46.2119. ［5］ Ladetto, M, Brüggemann M, Monitillo L, et al. Nextgeneration sequencing and realtime quantitative PCR for minimal residual disease detection in Bcell disorders［J］. Leukemia, 2014, 28(6): 12991307. DOI: 10.1038/leu.2013.375. ［6］ Bai Y, Wong KY, Fung TK, et al. High applicability of ASORQPCR for detection of minimal residual disease in multiple myeloma by entirely patientspecific primers/probes［J］. J Hematol Oncol, 2016, 9(1): 107. ［7］ MartinezLopez J, FernándezRedondo E, GarcíaSánz R, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescentPCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study［J］. Br J Haematol, 2013, 163(5): 581589. DOI: 10.1111/bjh.12576. ［8］Faham M, Zheng J, Moorhead M, et al. Deepsequencing approach for minimal residual disease detection in acute lymphoblastic leukemia［J］. Blood, 2012, 120(26): 51735180. DOI: 10.1182/blood201207444042. ［9］ MartinezLopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma［J］. Blood, 2014, 123(20): 30733079. DOI: 10.1182/blood201401550020. ［10］ Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQPCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry［J］. Leukemia, 2014, 28(2): 391397. DOI: 10.1038/leu.2013.217. ［11］ Silvennoinen R, Lundan T, Kairisto V, et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQPCR in multiple myeloma［J］. Blood Cancer J, 2014, 4: e250. DOI: 10.1038/bcj.2014.69. ［12］ Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation［J］. Blood, 2008, 112(10): 40174023. DOI: 10.1182/blood200805159624. ［13］ de Tute RM, Rawstron AC, Gregory WM, et al. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen［J］. Haematologica, 2016, 101(2): e69e71. DOI: 10.3324/haematol.2015.128215. ［14］ Ladetto M, Ferrero S, Drandi D, et al. Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma［J］. Leukemia, 2016, 30(5): 12111214. DOI: 10.1038/leu.2015.269. ［15］ de Larrea CF, Cibeira MT, Elena M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition［J］. Blood, 2009, 114(24): 49544956. DOI: 10.1182/blood200906224832. ［16］ Mateos MV, Oriol A, MartinezLópez J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?［J］. Blood, 2014, 124(12): 18871893. ［17］ Ferrero S, Ladetto M, Drandi D, et al. Longterm results of the GIMEMA VEL03096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics′ impact on survival［J］. Leukemia, 2015, 29(3): 689695. DOI: 10.1038/leu.2014.219.

多发性骨髓瘤微小残留病的检测方法及临床应用

Detection and clinical application of minimal residual disease in multiple myeloma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价